Dyne Therapeutics, Inc. (DYN)
NASDAQ:DYN
Want to see DYN full AI Analyst Report?
DYN Stock Chart & Stats
$20.41
-$0.74(-3.10%)
At close: 4:00 PM EST
$20.41
-$0.74(-3.10%)
Day’s Range― - ―
52-Week Range$8.06 - $25.00
Previous CloseN/A
Volume117.44K
Average Volume (3M)1.51M
Market Cap
$2.97B
Enterprise Value$2.46B
Total Cash (Recent Filing)$972.16M
Total Debt (Recent Filing)$19.30M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Jul 30, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.22
Shares Outstanding165,313,800
10 Day Avg. Volume1,567,812
30 Day Avg. Volume1,507,935
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.30K
Enterprise Value/Ebitda-5.58
Forecast
1Y Price Target
$37.91Price Target Upside85.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary FORCE PlatformDyne’s FORCE platform targets delivery of antisense and other payloads to muscle tissue, a structural technical advantage for neuromuscular indications. If validated, the platform can be reused across programs, lowering incremental development risk and creating durable differentiation and scale in R&D and manufacturing.
Clinical And Regulatory ProgressCompleting ACHIEVE enrollment and pursuing defined registrational pathways materially de-risks near-term development timelines. These execution milestones improve probability of regulatory submissions and potential accelerated approvals, creating a clearer path to commercialization and partnering opportunities over the coming years.
Low Leverage Balance SheetVery low debt reduces solvency and covenant risk while preserving strategic optionality for financing or partnerships. This structure gives management flexibility to fund late-stage trials or seek collaborations without immediate refinancing pressure, supporting medium-term program continuation if capital markets remain accessible.
Bears Say
No Product RevenueAs a clinical-stage biotech with no product sales, Dyne lacks recurring cash inflows from commercialization. Long-term sustainability therefore depends on trial success and capital market access; failure to convert programs to approved products creates structural revenue risk and increases reliance on external funding.
High And Worsening Cash BurnSustained negative operating and free cash flow at scale will deplete resources absent material milestone payments or financings. This persistent burn forces frequent capital raises, risks shareholder dilution, and constrains the company’s ability to advance multiple programs concurrently or absorb trial setbacks without restructuring.
Widening Net Losses And Negative ROEGrowing net losses and deeply negative return on equity show the capital base is not generating economic returns. This erosion of equity through operating losses reduces financial resilience, increases the likelihood of dilutive financing, and could pressure strategic pivots or asset prioritization if clinical readouts disappoint.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics, Inc.’s price range in the past 12 months?
Dyne Therapeutics, Inc. lowest stock price was $8.06 and its highest was $25.00 in the past 12 months.
What is Dyne Therapeutics, Inc.’s market cap?
Dyne Therapeutics, Inc.’s market cap is $2.97B.
When is Dyne Therapeutics, Inc.’s upcoming earnings report date?
Dyne Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 55 days.
How were Dyne Therapeutics, Inc.’s earnings last quarter?
Dyne Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.772 by $0.042.
Is Dyne Therapeutics, Inc. overvalued?
According to Wall Street analysts Dyne Therapeutics, Inc.’s price is currently Undervalued.
Does Dyne Therapeutics, Inc. pay dividends?
Dyne Therapeutics, Inc. does not currently pay dividends.
What is Dyne Therapeutics, Inc.’s EPS estimate?
Dyne Therapeutics, Inc.’s EPS estimate is -0.75.
How many shares outstanding does Dyne Therapeutics, Inc. have?
Dyne Therapeutics, Inc. has 165,313,800 shares outstanding.
What happened to Dyne Therapeutics, Inc.’s price movement after its last earnings report?
Dyne Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.772. Following the earnings report the stock price went up 4.827%.
Which hedge fund is a major shareholder of Dyne Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyne Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.91 (85.74% Upside)
$37.91 (85.74% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $197.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Bullish
Bullish news 79%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.28%
12-Months-Change
Fundamentals
Return on Equity
-58.28%
Trailing 12-Months
Asset Growth
49.77%
Trailing 12-Months
Company Description
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
DYN Stock 12 Month Forecast
Average Price Target
$37.91
▲(85.74% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
3.90% Insiders
24.20% Mutual Funds
9.89% Other Institutional Investors
47.98% Public Companies and Individual Investors